# RefleXion Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/reflexion-medical

- Industry: Medical Devices & Equipment
- Headquarters: Hayward, US
- Website: www.reflexion.com
- Total disclosed funding: $453M
- Latest round: Series F (Nov 13, 2023)
- Investors on record: 17

## About

Founded in 2009 by Samuel Mazin and Akshay Nanduri, and based in Hayward, CA, RefleXion Medical, Inc. specializes in advanced radiotherapy solutions, focusing on innovative treatments for cancer. Their flagship product, SCINTIX®, enhances precision in targeting tumors while minimizing damage to healthy tissue. RefleXion Medical, Inc. has raised a total of USD 650.98 million across 11 rounds of funding, with the most recent deal being a series F round of funding in which the company secured USD 106.71 million. The latter deal values RefleXion Medical, Inc. at USD 1.22 billion. This innovative technology detects and responds to biological signals emitted by cancer cells, enabling immediate treatment of solid tumors located in the lung or bone, including those from primary or metastatic sources. SCINTIX therapy facilitates high-dose radiation delivery to tumors, even those in motion, while minimizing exposure to surrounding healthy tissues. The company primarily markets its products to medical institutions and cancer treatment centers within the United States and select international markets, enhancing patient outcomes through advanced oncology solutions. RefleXion Medical, Inc. generates revenue through direct sales of its SCINTIX therapy systems and associated services to hospitals and cancer treatment centers. Transactions typically occur via partnerships with healthcare providers, establishing contracts that facilitate the integration of the SCINTIX platform into cancer treatment programs. The revenue model is primarily B2B, focusing on direct sales rather than retail channels, and clients may engage in multi-year agreements that include ongoing support and training.

## Funding rounds

- Series F, Nov 13, 2023, $107M — T Rowe Price, TPG, Venrock, Johnson & Johnson Innovation, Pfizer Venture Investments, Hillenbrand, Pictet Alternative Advisors, Ally Bridge Group, Squarepoint, Catalio Capital Management
- Series E, Mar 1, 2022, $81M — T Rowe Price, TPG, Venrock, Johnson & Johnson Innovation, Public Sector Pension Investment Board, Ascension Ventures, Hillenbrand Capital Partners, Pfizer Venture Investments, Ally Bridge Group, KCK Group, Catalio Capital Management, Sixty Degree Capital
- Series D, Mar 2, 2021, $40M — Ally Bridge Group
- Series D, Apr 3, 2020, $100M — Sofinnova Partners, T Rowe Price, TPG, Venrock, Johnson & Johnson Innovation, Public Sector Pension Investment Board, Pfizer Venture Investments, KCK Group
- Series C, Mar 16, 2018, $97M — Sofinnova Partners, T Rowe Price, TPG, Venrock, Johnson & Johnson Innovation, Pfizer Venture Investments, KCK Group, GT Healthcare Capital Partners
- Series B, Apr 5, 2016, $23M — Sofinnova Partners, Venrock, Pfizer Venture Investments, KCK Group
- Series A, Mar 20, 2014, $6.1M — Sofinnova Partners, Venrock, Pfizer Venture Investments

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A, Series B, Series C, Series D
- Venrock (https://capitalatlas.ai/funds/venrock) — Series A, Series B, Series C, Series D, Series E, Series F
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series A, Series B, Series C, Series D, Series E, Series F
- KCK Group — Series B, Series C, Series D, Series E
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series C, Series D, Series E, Series F
- TPG (https://capitalatlas.ai/funds/tpg) — Series C, Series D, Series E, Series F
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series C, Series D, Series E, Series F
- GT Healthcare Capital Partners (https://capitalatlas.ai/funds/gt-healthcare-capital-partners) — Series C
- Public Sector Pension Investment Board — Series D, Series E
- Ally Bridge Group (https://capitalatlas.ai/funds/ally-bridge-group) — Series D, Series E, Series F
- Ascension Ventures (https://capitalatlas.ai/funds/ascension-ventures) — Series E
- Hillenbrand Capital Partners — Series E
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series E, Series F
- Sixty Degree Capital (https://capitalatlas.ai/funds/sixty-degree-capital) — Series E
- Hillenbrand — Series F
- Pictet Alternative Advisors (https://capitalatlas.ai/funds/pictet-alternative-advisors) — Series F
- Squarepoint — Series F